The recent advances in CAF-based therapy are based on targeting the markers to ablate CAFs, restoring activated CAFs to quiescent ones, and blocking the signalling between CAFs and tumour cells, such as JAK1/JAK2 and CXCL12/CXCR [147,254,255,256]. The gene discussed is JAK2; the disease is neoplasm.